loading...| Preferred Name |
pravastatin sodium |
| Synonyms |
PRAV |
| Definitions |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29375" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29375" NCI Thesaurus) |
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000424450 |
| altLabel |
PRAV Pravachol |
| CAS Registry |
81131-70-6 |
| Component of | |
| cui |
C0700763 C0085542 C0700474 |
| DATE FIRST PUBLISHED |
2005-03-24 |
| Date last modified |
2017-12-13 |
| definition |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29375" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29375" NCI Thesaurus) |
| LT |
TRD |
| NCI ID |
C29375 |
| notation |
CDR0000424450 |
| ORIG STY |
Drug/agent |
| prefLabel |
pravastatin sodium |
| tui |
T109 T121 |